Citations

Clear

846 citation(s) found for "Li, Min".

Prevalence of Concurrent (Double‐Positive) JAK2 , CALR , or MPL Mutations and Corresponding Clinicopathologic Featu
He, Rong , Ollila, Paul L., Zhang, Xi , Ji, Yuan , Rangan, Aruna , Gangat, Naseema , Chen, Dong , Tefferi, Ayalew , Viswanatha, David S., Yuan, Ji , Chen, Dong , Tefferi, Ayalew , Shi, Min

Mayo Clinic

American Journal of Hematology | October 4, 2025 | Volume: 100 | Issue: 12 | Pages: 2431-2435

10.1002/ajh.70098 | PMID 41045031 Get It

Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits
Shaw, Vikram R. , Byun, Jinyoung , Thrift, Aaron P. , Zhu, Catherine , Li, Donghui , Kelley, Robin Kate , Bracci, Paige M. , Bucur, Roxana , Knox, J. David, Jalal, Prasun K. , Ghobrial, R. Mark , Nguyen, Mindie H. , Parikh, Neehar D. , Wu, Hui‐Chen , El‐Serag, Hashem, Chang, Ping , Chun, Yun Shin , Gu, Jian , Huff, Chad D. , Rashid, Asif, Hwang, Lu‐Yu, Khaderi, Saira, Roberts, Lewis R. , Hassan, Manal M. , Shaw, Vikram R , Byun, Jinyoung , Thrift, Aaron P , Permuth, Jennifer B , Yuan, Jian-Min , Nguyen, Mindie H , Kim, Richard , Gu, Jian , Kaseb, Ahmed O , McGlynn, Katherine A , Roberts, Lewis R , Parikh, Neehar D , Jalal, Prasun K , Han, Younghun , Hatia, Rikita , Cleary, Sean P. , Lok, Anna S. , Permuth, Jennifer B. , Knox, Jennifer, Singal, Amit G. , Kono, Yuko , Shah, Dimpy P. , Kim, Richard D. , El‐Serag, Hashem B. , Rashid, Asif , Klein, Alison P. , McGlynn, Katherine A. , Amos, Christopher I.

Mayo Clinic

International Journal of Cancer | September 27, 2025 | Volume: 158 | Issue: 5 | Pages: 1193-1203

10.1002/ijc.70136 | PMID 41013983 Get It

Abstract Hepatocellular carcinoma (HCC) mortality is increasing globally, partly due to the growing prevalence of nonviral liver diseases. Genome‐wide association studies (GWAS) have identified genetic variants associated with HCC development. Leveraging GWAS summary statistics and linkage disequilibrium score regression (LDSR), we investigated disease co‐development with hepatitis C virus‐negative (HCV‐negative) HCC to provide unique insights into HCC etiology and prioritize relationships for further causal inquiry. We utilized the LDSR statistical framework to estimate the genetic correlation and heritability between HCV‐negative HCC with 901 epidemiologic, behavioral, and clinical traits from the United Kingdom Biobank (UKBB). First, we set the threshold for observed scale heritability of each trait at 0.02 to ensure reliable inferences with adequate study power. Next, we observed significant positive genetic correlations between HCV‐negative HCC and blood‐based biomarkers of liver injury (ALT, GGT) and allostatic load (including glycated hemoglobin, blood pressure, and total albumin). We also identified a positive genetic correlation between HCV‐negative HCC and diseases associated with metabolic dysfunction‐associated steatotic liver disease (MASLD), including diabetes, hypertension, chronic ischemic heart disease, and others. Taken together, our results help to identify polygenic and pleiotropic signals related to different phenotypic traits associated with HCC and support further exploration of the predictive power of blood‐based biomarkers identified in this study for inferring HCC development among HCV‐negative individuals.
Advancing delirium detection through the Open Health Natural Language Processing Consortium and the Evolve to Next-Gen Accrual to Clinical Trials Network
Fu, Sunyang , Kwak, Min Ji , Ahn, Jaerong, Yue, Zhiyi , Ranganath, Shreyas, Applegate, Joseph R., Wang, Liwei , Li, Chenyu , Toth, Kelly M, Girard, Timothy D., Osborne, John D. , Kennedy, Richard , Garduno-Rapp, Nelly-Estefanie, Reeder, Phillip , Murphy, Thomas J. , Heling, Jia, Sohn, Sunghwan , Visweswaran, Shyam, Wang, Yanshan , Girard, Timothy D. , Li, Chenyu , Rousseau, Justin F , Yan, Chao , Murphy, Tyler J , Park, Chan Mi , Bernstam, Elmer V , Visweswaran, Shyam , Liu, Hongfang , Girard, Timothy D , Fu, Sunyang , Kennedy, Richard E , Osborne, John D , Wang, Yanshan , Ahn, Jaerong, Applegate, Joseph R, Wen, Andrew , Morris, Michele M. , Toth, Kelly M, Rousseau, Justin F. , Chen, You , Patel, Mayur Bipin , Malin, Bradley , Jia, Heling, Pagali, Sandeep R. , Palmer, Allyson K. , Sauver, Jennifer L. St. , Liu, Hongfang

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | September 26, 2025 | Volume: 80 | Issue: 12 | Pages: No page available

10.1093/gerona/glaf207 | PMID 41017643 Get It

Abstract Background Delirium is often underdiagnosed in clinical practice and is not routinely coded for billing. While manual chart review can identify delirium, it is labor-intensive and impractical for large-scale studies. Natural language processing (NLP) can analyze unstructured text in electronic health records (EHRs) to extract meaningful clinical information. Methods To support national integration of NLP for EHR-based delirium identification across different institutions, we launched the Delirium Interest Group within the national Evolve to Next-Gen Accrual to Clinical Trials (ENACT) NLP Working Group. This paper outlines our initial efforts to standardize, evaluate, and translate an NLP-based delirium detection model into the i2b2/ENACT platform. Results Multisite contextual inquiry identified several key challenges, including variations in local screening practices (eg, tools used, documentation frequency, and quality control), the need for harmonized definitions in the context of EHRs, and the complexity of modeling temporal logic. Multisite NLP evaluation revealed variable performance degradation driven by differences in delirium screening practices, clinical documentation patterns and semantics, and note syntactic structures. Conclusion Our work represents an important first step toward enabling scalable and standardized NLP-based delirium detection across institutions. By engaging diverse institutions through the ENACT NLP Working Group, we identified shared challenges and site-specific variations that impact model implementation and performance. Our collaborative approach enabled the development of a more robust framework for delirium identification across heterogeneous EHR systems. Future efforts will build on this foundation to enhance the validity, usability, and translational impact of delirium detection.
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study
Thompson, Carrie A. , Trněný, Marek , Morschhauser, Franck , Salles, Gilles , Reagan, P. M., Hertzberg, Mark P. , Zhang, Huilai , Thiéblemont, Catherine , Fonseca, Gustavo , Kim, W., Singh, Avrita, Yan, Mark, Hirata, Jamie , Sugidono, Matthew , Lee, Calvin , Sharman, Jeff P. , Mehta–Shah, Neha , Flowers, Christopher R. , Tilly, Hervé , Chua, Neil , Miall, Fiona , Tsai, Cheng‐Hong , Friedberg, Jonathan W. , Thompson, Carrie, Hu, Bei , Hirata, Jamie , Mehta-Shah, Neha , Flowers, Christopher R , Casasnovas, René-Olivier , Miall, Fiona , Kim, Tae Min , Tsai, Xavier Cheng-Hong , Salles, Gilles A , Morschhauser, Franck , Trnĕný, Marek , Hertzberg, Mark, Hu, Bei , Martelli, Maurizio , Mehta, Amitkumar , Singh, Avrita, Casasnovas, Olivier , Nasta, Sunita , Lee, Seung‐Tae

Mayo Clinic

Blood | September 25, 2025 | Volume: 147 | Issue: 3 | Pages: 254-265

10.1182/blood.2025028848 | PMID 40997297 Get It

Abstract Diffuse large B-cell lymphoma (DLBCL) poses a challenge in hematology given its varied symptoms, and the complex interplay between disease and treatment effects on health-related quality of life (HRQoL). The phase 3 POLARIX study demonstrated superior progression-free survival and a similar safety profile with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated DLBCL. Here, we evaluate HRQoL through patient-reported outcome (PRO) instruments to fully characterize the patient experience in the POLARIX study. Changes from baseline in HRQoL, lymphoma symptoms, and gastrointestinal (GI) symptoms were assessed, as well as incidence and severity of common symptoms by PROs vs clinician-reported adverse events (AEs). Baseline characteristics of PRO-evaluable patients (N = 874) were consistent. Comparison between PROs and clinician-reported AEs revealed a notable discordance; patients generally reported a higher incidence of symptoms than clinicians, emphasizing the need for patient-centric tools to accurately capture the patient experience. Both treatments exhibited rapid and sustained improvements in HRQoL and lymphoma symptoms, with the most substantial improvements seen in global health status/QoL, lymphoma symptoms, fatigue, role, emotional, and social functioning. GI symptoms (diarrhea, constipation, nausea, and vomiting) were generally similar between treatment arms and returned to baseline levels after treatment completion. These HRQoL data underscore the complementarity of PROs, as an adjunct to clinician-reported AEs, in evaluating the efficacy and tolerability of new treatments, including Pola-R-CHP, which may represent a new benchmark for patient-reported HRQoL in previously untreated DLBCL. This trial was registered at www.clinicaltrials.gov as NCT03274492.
Natural history of nonfunctioning pituitary microadenomas: a systematic review and individual participant data meta-analysis
Boesen, Victor Brun , Hansen, T H, Motawea, Mohammad, Fleseriu, Maria , Varlamov, Elena V , Han, Ashley J , Imran, S A, Munro, Vicki , Alenazi, Mohammed , Lenders, Nèle F , Damilano, Roxana A, Monteserin, Natalia L, Lania, Andrea , Carosi, Giulia , Hordejuk, Dawid, Min, Le , Kaiser, U B, Rikvold, Stefan Dukanovic, Boesen, Victor B , Lenders, Nele , Lania, Andrea G , Mantovani, Giovanna , Min, Le , Krogh, Jesper , Inder, Warrick John , Fleseriu, Maria

Mayo Clinic

European Journal of Endocrinology | September 22, 2025 | Volume: 193 | Issue: 4 | Pages: S61-S70

10.1093/ejendo/lvaf189 | PMID 40982460 Get It

Abstract Objective Increased frequency of neuroimaging has led to enhanced identification of small nonfunctioning pituitary adenomas (NFPAs) leading, in many cases, to extensive follow-up. However, the value of ongoing monitoring of these incidental lesions remains unclear. The study aims to determine the need for surgical intervention and assess the risks of developing new endocrinopathies during follow-up in patients with conservatively treated micro-NFPAs. Design A systematic review and individual participant data (IPD) meta-analysis. Methods We conducted a bibliographical search of PubMed and EMBASE to identify relevant studies. Authors of eligible studies were invited to share IPD. Cohort studies including patients with conservatively treated micro-NFPAs with at least 1 follow-up magnetic resonance imaging were considered eligible. Fourteen studies met inclusion criteria. Six authors provided IPD (N = 647). Data were reanalyzed for verification. In cases of discrepancies the original authors were contacted for authentication. Results Risk estimates were reported as number of events per 100 person-years (PYs). Estimates were pooled using the 2-step approach. Overall probability of surgery was 0.2/100 PYs (95% CI: 0.0-0.4; I2 = 28%). Probability of surgery due to visual impairment was 0.1/100 PYs (95% CI: 0.0-0.2; I2 = 0%). Both were independent of baseline tumor size (≥6 or <6 mm), sex, or age (P values >.40). Risk of developing a new endocrinopathy was 1.0/100 PYs (95% CI: 0.4-1.6; I2 = 0%). Data for classical meta-analysis were available for 7 studies (N = 1089) and supported the IPD results. Conclusions These data suggest that routine follow-up of micro-NFPAs can be reduced significantly and that available guidelines should be revisited.
Procedure duration predicts outcomes more than prehospital delay in endovascular stroke treatment
Saad, Hassan , Koo, Andrew B. , Grossberg, Jonathan A , Tianwen, Ma, Howard, Brian M. , Sowlat, Mohammad‐Mahdi , Baba, Bachar El , Chacón, Ariana , Jabbour, Pascal , Rai, Ansaar , Dye, Justin , Alaraj, Ali , Cawley, C. Michael , Tong, Frank , Akbik, Feras , Pabaney, Aqueel, Ezzeldin, Mohamad , Kim, Joon‐Tae , Siddiqui, Fazeel , Maier, Ilko , Park, Min S. , Psychogios, Marios‐Nikos, Wolfe, Stacey Q , Starke, Robert M. , Tanweer, Omar , Polifka, Adam , Mokin, Maxim, Brinjikji, Waleed , Dağlıoğlu, Ergün , Williamson, Richard , Altschul, David , Ogilvy, Christopher S. , Crosa, Roberto , Gory, Benjamin , Kan, Peter , Casagrande, Walter, Chowdhry, Shakeel , Stiefel, Michael , Spiotta, Alejandro M , Ma, Tianwen , El Baba, Bachar , Fiorella, David , Yoshimura, Shinichi , Kim, Joon-Tae , Arthur, Adam Stephen , Fragata, Isabel , Siddiqui, Fazeel M , Matouk, Charles , Maier, Ilko , Levitt, Michael R , Grandhi, Ramesh , Wolfe, Stacey Quintero , Shaban, Amir , Navia, Pedro , Osbun, Joshua W , Brinjikji, Waleed , Altschul, David J , Ogilvy, Christopher S , Crosa, Roberto , Paul, Alexandra R , Kan, Peter , Spiotta, Alejandro M , Alawieh, Ali M , Alaraj, Ali , Sowlat, Mohammad-Mahdi , Howard, Brian M , Koo, Andrew B , Chacón-Aponte, Ariana Alejandra , Jabbour, Pascal , Fiorella, David , Yoshimura, Shinichi , Goyal, Nitin , Fragata, Isabel , Mascitelli, Justin R , Matouk, Charles , Levitt, Michael R. , Grandhi, Ramesh , Samaniego, Edgar A , Romano, Daniele G, Navía, Pedro , Cuellar, Hugo , Moss, Mark E, Limaye, Kaustubh , Mokin, Maxim , Gory, Benjamin , Alawieh, Ali

Mayo Clinic

Journal of NeuroInterventional Surgery | September 19, 2025 | Volume: 18 | Issue: 6 | Pages: 1494-1502

10.1136/jnis-2025-023906 | PMID 40973492 Get It

Background Endovascular thrombectomy (EVT) has transformed acute ischemic stroke (AIS) care, with onset-to-puncture (OTP) time widely recognized as a critical determinant of outcome. However, emerging evidence suggests that in-hospital procedure time (PT)—from arterial puncture to final recanalization—may have an equally or more significant impact. This study examines the relative contribution of PT versus OTP to functional outcomes in patients with AIS undergoing EVT. Methods A retrospective analysis was conducted of 6644 patients with AIS treated at 44 international stroke centers from the Stroke Thrombectomy and Aneurysm Registry (STAR; 2016–2023). Multivariable regression, time-equivalence analysis, and marginal effects modeling were used to assess associations between PT, OTP, and 90-day modified Rankin Scale (mRS) outcomes. Centers were stratified by procedural efficiency and compared using propensity score matching (PSM). Mediation analysis evaluated whether PT accounted for inter-center differences. Results PT and OTP were independently associated with functional outcomes; however, PT had a significantly stronger effect (adjusted OR for mRS 0–2: PT=0.56 vs OTP=0.96 per hour). Each 5 min increase in PT was equivalent to 78–100 min of additional OTP in outcome impact. Centers with faster average PT had higher rates of functional independence (number needed to treat (NNT)=10), fewer complications, and lower symptomatic intracranial hemorrhage rates. PT significantly mediated the relationship between center tier and outcomes (Sobel’s P<0.001). Conclusion While minimizing OTP remains important, PT exerts a greater influence on outcomes after EVT. Procedural efficiency should be emphasized in stroke systems of care and included in center performance metrics to improve patient outcomes.
Predictors of Intracranial Aneurysm Residual Filling After Treatment With Flow Diversion at Early Follow-up: A Multicenter Experience of 2277 Patients
Burks, Joshua D. , Abdelsalam, Ahmed , Silva, Michael A. , Jabbour, Pascal, Kasab, Sami Al , Kan, Peter , Chalouhi, Nohra , Eatz, Tiffany , Wolfe, Stacey Q , Spiotta, Alejandro M , Yavagal, Dileep R. , Peterson, Eric C. , Wu, Eva M. , Lanzino, Giuseppe, Brinjikji, Waleed , El‐Ghanem, Mohammad , Starke, Robert M. , Wolfe, Stacey Quintero , Luther, Evan , Christopher, Kara M , Jabbour, Pascal, Levitt, Michael R. , Sanikommu, Sai , Abla, Adib A. , Arthur, Adam Stephen , Osbun, Joshua W , Park, Min S. , Sweid, Ahmad , Fargen, Kyle M , Peterson, Eric C., Schirmer, Clemens M. , Almallouhi, Eyad , Lanzino, Giuseppe

Mayo Clinic

Neurosurgery | September 19, 2025 | Volume: 98 | Issue: 1 | Pages: 239-245

10.1227/neu.0000000000003747 | PMID 40970720 Get It

BACKGROUND AND OBJECTIVES: Flow-diverting stents (FDSs) have improved treatment options for intracranial aneurysms. Although FDS have proven successful in treating aneurysms that would previously have required complex microsurgical or endovascular repairs, treatment failures remain a concern. In this multicenter study, we aim to analyze the predictors of residual aneurysmal filling at early angiographic follow-up. METHODS: A retrospective analysis of a prospectively maintained neuroendovascular database at 14 high-volume US centers was conducted for all patients who underwent FDS placement for intracranial aneurysms between 2011 and 2019. Aneurysms were graded on the O'Kelly-Marotta scale (OKM). RESULTS: A total of 2277 patients underwent FDS embolization for intracranial aneurysms during the study period. The patient's mean age was 55 (SD ± 13.5) years, and 82% were female. The median maximal aneurysm diameter was 6.7 mm (IQR 4.10-11 mm). Complete aneurysm obliteration (OKM grade 4) occurred in 1109 patients (68%), and 146 (9%) were OKM grade 3, 188 (12%) were OKM grade 2, and 174 (11%) were OKM grade 1. In the adjusted multivariate analysis, individuals in the 65-74 years and 75+ years age groups had significantly increased risk of residual aneurysm filling at 6-month follow-up compared with the 18-44 years age group (odds ratio [OR] 1.92 (95% CI: 1.33-2.78) and 2.92 (95% CI: 1.79-4.77), respectively). Aneurysms arising from the superior cerebellar artery, the basilar artery, and the carotid terminus were more likely to have a residual filling (OR 12.6, 95% CI: 1.39–14.7; OR 4.27, 95% CI: 1.39–14.7; OR 3.16, 95% CI: 1.24–8.06, respectively). CONCLUSION: As the utilization of FDS for intracranial aneurysms becomes more widespread, the efficacy of aneurysm obliteration needs to be assessed. Our results indicate that several patient-dependent factors, such as age, aneurysm location, and size, predict the likelihood of residual aneurysm filling 6 months post-treatment.
Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry
Seheult, Jansen N. , Otteson, Gregory E., Timm, Michael, Weybright, Matthew J. , Shi, Min , Olteanu, Horatiu , Chen, Chuan , Chiu, April , Timm, Michael M, Chen, Chuan , Chiu, April , Shi, Min , Seheult, Jansen N , Jevremović, Dragan , Horna, Pedro

Mayo Clinic

Blood Advances | September 18, 2025 | Volume: 10 | Issue: 1 | Pages: 58-69

10.1182/bloodadvances.2025016126 | PMID 40966417 Get It

Abstract Measurable residual disease (MRD) assessment by flow cytometry (FC) plays an essential role in prognosis and therapy escalation of B-cell acute lymphoblastic leukemia (B-ALL). However, the high degree of expertise and manual analysis time required limits the availability of this assay. To overcome this limitation, we developed a data-enhancing artificial intelligence (AI) pipeline that accelerates and simplifies MRD analysis. Unaltered FC files from 171 B-ALL MRD-positive and 89 MRD-negative cases were processed through an AI pipeline trained with 31 expert-gated negative controls. Cluster-informed downsampling reduced FC files from 1.2 million to 155 884 cells per case, on average, (87% cellularity reduction), whereas preserving small MRD populations (median, 100% retention for MRD of &lt;1%) and allowing for true percentage MRD estimates using a correction factor. A deep neural network cell classifier automatically identified normal hematopoietic subsets (macro-averaged F1 score of 0.86); and an AI measure of anomaly discriminated B-ALL from benign mononuclear (area under the curve [AUC] of 0.98) or B-lymphoid cells (AUC of 0.94). Manual analysis of AI-enhanced files was completed in only 1.01 minutes per case, on average (standard deviation of ±0.57); with 100% positive agreement with conventional analysis (for MRD of ≥0.01%), 100% negative agreement, and excellent quantitative correlation (R2 = 0.92). Our cloud-based AI-enhancement solution accelerates B-ALL MRD identification without compromising test performance and has the potential of facilitating B-ALL MRD analysis by more clinical laboratories.
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Blechter, Batel , Wang, Xiaoyu , Karsonaki, Christiana, Shi, Jianxin , Shiraishi, Kouya , Choi, Jiyeon , Matsuo, Keitaro , Chen, Tzu‐Yu , Kim, Young Tae , Choudhury, Parichoy Pal , Williams, Jacob , Landi, Maria Teresa , Yin, Zhihua , Zhou, Baosen , Seow, Wei Jie , Song, Lei , Chang, I‐Shou , Chien, Li-Hsin , Wong, Maria Pik , Richardson, Brian Douglas , Li, Shilan , Breeze, Charles E. , Bassig, Bryan A. , Sm, Jason Yy Wong, Chung, Lap Ping, Zhang, Xu‐Chao , Caporaso, Neil E. , Chang, Jiang , Ho, Jcm , Momozawa, Yukihide , Kobayashi, Masashi , Okubo, Kenichi , Honda, Takayuki , Kunitoh, Hideo , Watanabe, Shun-ichi, Hamamoto, Ryuji , Goto, Kōichi , Minamiya, Yoshihiro, Wakai, Kenji , Murakami, Yoshinori , Shimizu, Kimihiro , Suzuki, Hiroyuki , Ohtaki, Yoichi , Tanaka, Kazumi , Wu, Tangchun , Wei, Fusheng, Kim, Yeul Hong , Chang, Gee-Chen , Chen, Kuan‐Yu, Chen, Yuh-Min, Park, Jae Yong , Kweon, Sun-Seog, Gao, Yu‐Tang , Schwartz, Ann G. , Gorlov, Ivan , Wu, Xifeng , Yang, Ping , Lam, Stephen , Bojesen, Stig E. , Ji, Bu‐Tian , Wichmann, H. E., Christiani, D.C., Brennan, Paul , McKay, James , Field, John K. , Shete, Sanjay , Marchand, Loı̈c Le, Liu, Geoffrey , Andrew, Angeline S. , Zienolddiny-Narui, Shan, Grankvist, Kjell , Taylor, Fiona, Aldrich, Melinda C. , Jeon, Hyo‐Sung, Hu, Zhibin , Burdett, Laura, Yeager, Meredith, Hutchinson, Amy , Hicks, Belynda , Liu, Jia , Berndt, Sonja I, Wu, Wei , Wang, Junwen , Choi, Jin Eun , Park, Kyong Hwa , Sung, Sook Whan , Tan, Wen , Sihoe, Alan , Choi, Yi Young, Hung, Hsiao-Han , Vermeulen, Roel , Wu, Junjie , Tsai, Fang-Yu , Chan, John K. C., Li, Jihua , Lin, Hsien-Chih, Liu, Jie , Sawada, Norie , Yamaji, Taiki , Wyatt, Kathleen , Qi, T. Y., Li, Xuelian , Ren, Yangwu , Chao, Ann, Zhu, Junjie , Chen, Chih‐Yi , ScD, Chien-Jen Chen, Stevens, Victoria L. , Fraumeni, Joseph F., Lin, Kuang , Walters, Robin G., Chen, Zhengming, Chatterjee, Nilanjan , Gorlova, Olga Y. , Hsiung, Chao A. , Chanock, Stephen J, Rothman, Nathaniel , Kohno, Takashi , Lan, Qing, Kartsonaki, Christiana , Liu, Geoffrey , Field, John K , Matsuo, Keitaro , Wang, Junwen , Bojesen, Stig E , Grankvist, Kjell , Chen, Chih-Yi , Dai, Juncheng , Hung, Rayjean J. , Chen, Kexin , Shu, Xiao-Ou , Choudhury, Parichoy Pal , Lin, Dongxin , Zheng, Wei , Wang, Jiucun , Hu, Wei , Cai, Qiuyin , Hong, Yun‐Chul , Kim, Hee Nam , Wu, Yi-Long Lung Cancer , Richardson, Brian Douglas , Zhang, Tongwu , Wang, Zhaoming , Kim, Jin Hee , Albanes, Demetrius , Shin, Min‐Ho , Chung, Lap-Ping, Yang, Yang , Zheng, Hong , Dai, Hong , Yatabe, Yasushi , Kim, Young‐Chul , Daigo, Yataro , Kamatani, Yoichiro , Kobayashi, Masashi , Hosgood, Howard Dean , WATANABE, Shun-ichi J. , Miyagi, Yohei , Matsumoto, Shingo , Horinouchi, Hidehito , Tsuboi, Masahiro , Takahashi, Atsushi , Goto, Akiteru , Hara, Megumi , Nishida, Yuichiro , Takeuchi, Kenji , Matsuda, Koichi , Murakami, Yoshinori, Suzuki, Hiroyuki , Saito, Motonobu , Machiela, Mitchell J. , Oh, In‐Jae , Lee, Victor , Su, Wu‐Chou , Seow, Adeline , Kweon, Sun-Seog , Liu, Jianjun , Houlston, Richard S. , Tardón, Adonina , Chen, Chu, Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Rennert, Gad , Arnold, Susanne M. , Davies, Michael P.A. , Kiemeney, Lambertus A. , Cox, Angela , Yuan, Jian-Min , Lazarus, Philip J. , Schabath, Matthew B. , Jiang, Shih Sheng , Chen, Chung–Hsing , Hsiao, Chin‐Fu , Yeager, Meredith , Liu, Jia , Berndt, Sonja I. , Li, Yuqing , Kang, Chang Hyun , Wang, Wen‐Chang , Xu, Jun, Guan, Peng , Yu, Chong‐Jen , Yang, Gong , Park, In Kyu , Cheng, Iona C. , Song, Bao, Wyatt, Kathleen , Ma, Hongxia , Zhu, Meng , Wang, Yifan , Qi, Tianchen, Iwasaki, Motoki , Wu, Guoping , Yang, Pan‐Chyr , Walters, Robin G. , Chatterjee, Nilanjan , Amos, Christopher I. , Shen, Hongbing , Rothman, Nathaniel , Lan, Qing , Zhang, Haoyu

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 18, 2025 | Volume: 118 | Issue: 2 | Pages: 231-249

10.1093/jnci/djaf272 | PMID 41032288 Get It

Abstract Background Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve lung adenocarcinoma risk prediction. Methods PRSs were developed using genome-wide association study summary statistics from East Asian (8002 cases; 20 782 controls) and European (2058 cases; 5575 controls) populations. Single-ancestry models included a PRS with 25 single nucleotide variants (PRS-25), PRS clumping and thresholding (CT), and LDpred2; multi-ancestry models included LDpred2 plus European PRS-128, PRS-CSx, and clumping and thresholding, super learning, empirical Bayes (CT-SLEB). Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium and externally validated in the Nanjing Lung Cancer Cohort. We assessed predictive accuracy via area under the curve operating procedure (AUC), with 10-year and (ages 30-80 years) absolute risks estimates. Results The best multi-ancestry PRS, using East Asian and European data via CT-SLEB, outperformed the best East Asian-only (LDpred2; AUC = 0.629, 95% confidence interval [CI] = 0.618 to 0.641), achieving an AUC of 0.640 (95% CI = 0.629 to 0.653) and odds ratio of 1.71 (95% CI = 1.61 to 1.82) per standard deviation increase. Nanjing Lung Cancer Cohort validation confirmed robust performance (AUC = 0.649, 95% CI = 0.623 to 0.676). The top 20% PRS group had a 3.92-fold higher lung adenocarcinoma risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year lung adenocarcinoma risk at age 50 years (0.42%) by age 41 years, 9 years earlier. Conclusions Multi-ancestry PRS approaches enhance lung adenocarcinoma risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.
MedError: A Machine-Assisted Framework for Systematic Error Analysis in Clinical Concept Extraction
Liu, Hongfang , Fu, Sunyang , Lu, Qiuhao , Ahn, Jaerong , Yin, Hanyun , Wen, Julia, Yue, Zhiyi , Harrison, Taylor, Jun, Jiang, Ruan, Xiaoyang , Wang, Liwei , Kwak, Min Ji , Wang, Yanshan , Huang, Ruihong , Ruan, Xiaoyang , Wen, Andrew , Wang, Yanshan , Fu, Sunyang , Liu, Hongfang , Chen, Fang , Wen, Julia, Harrison, Taylor, Jun, Jiang, Huang, Ming, Wen, Andrew , Wang, Liwei, Rianon, Nahid , Huang, Ruihong

Mayo Clinic

No container title available | September 17, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7151650/v1 | PMID 41001520 Get It

Abstract Error analysis is a critical step in evaluating and improving clinical concept extraction models, the most common clinical natural language processing (NLP) task. Unlike corpus annotation, which follows standardized protocols for creating gold-standard datasets, error analysis requires nuanced judgment grounded in both clinical expertise and NLP knowledge. This is especially important given the heterogeneity of clinical text, where variations in documentation style, note structure, and terminology can substantially influence model behavior. Despite its importance, there is currently no standardized, user-level framework to support systematic error analysis in clinical concept extraction task. In this study, we developed and validated MedError, a machine-assisted, human-in-the-loop framework designed to standardize and enhance error analysis for clinical concept extraction tasks. We collected and manually curated a corpus of 1,187 unique errors from a total of 4,237 notes across three different distinct hospitals. The error categories were defined using our previously validated error taxonomy and included 480 false negatives and 707 false positives across 25 error types and 48 clinical concept categories. We evaluated the performance of three proprietary and three open-source large language models (LLMs) in automatically classifying these errors into 26 and 15 predefined categories. We further developed a machine-assisted framework, MedError, which integrates best practices in error analysis, LLM-assisted classification and reasoning, and a user-friendly interface to enable more efficient, reproducible, and context-aware error analysis. The framework supports both single-site and federated multisite error analysis, facilitating the effective translation of clinical NLP systems into real-world settings.